Company / Operating Cash Flow
Taysha Gene Therapies, Inc. Operating Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$93.1M
FY2025
5-year range
-$117.0M / -$73.0M
FY2021-FY2025
Trend
-27.5%
vs FY2024
Sector context
#120 of 216
Health Care
What the data says
At -$93M, Taysha Gene Therapies, Inc.'s operating cash flow ranks #120 of 216 in the Health Care sector. Declined from -$88M to -$93M over the past 2 years.
Based on SEC 10-K filings.
-$93M in FY2025.
Declined from -$88M to -$93M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#120 of 216 in Health CareTop 56% of 216This company -$93.1M Sector average $658.7M
▼
-114.1% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 27.5% year-over-year.
- Ranks #120 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$93.1M | -27.5% |
| FY2024 | -$73.0M | +17.4% |
| FY2023 | -$88.4M | +24.5% |
| FY2022 | -$117.0M | +0.0% |
| FY2021 | -$117.0M | -280.9% |
| FY2020 | -$30.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026